Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GPR3 | P46089 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TYMS | P04818 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 6/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | MELK | Q14680 | 1/20 | 0.41 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13659576 | 0.80 | PARP1 (0.50) | PARP1KDM4EGPR3JAK2RPS6KA3 | |
| SCHEMBL29666517 | 0.75 | KDM4E (0.53) | PARP1KDM4EGPR3ALDH1A1PRKCI | |
| SCHEMBL6590915 | 0.75 | KDM4E (0.59) | PARP1KDM4EGPR3ALDH1A1PRKCI | |
| SCHEMBL6674377 | 0.75 | PARP1 (0.58) | PARP1TYMSMEN1KMT2APDPK1 | |
| SCHEMBL1479684 | 0.75 | ALDH1A1 (0.44) | PARP1KDM4EGPR3ALDH1A1PRKCI | |
| SCHEMBL16144839 | 0.73 | TYMS (0.54) | PARP1KDM4EGPR3ALDH1A1PRKCI | |
| SCHEMBL669508 | 0.73 | PARP1 (0.70) | PARP1KDM4EALDH1A1HSD17B10TDP1 | |
| SCHEMBL159416 | 0.72 | KDM4E (0.59) | KDM4EGPR3ALDH1A1HSD17B10TDP1 | |
| SCHEMBL31684807 | 0.72 | KDM4E (0.59) | KDM4EGPR3ALDH1A1HSD17B10TDP1 | |
| Hydrochloric Acid SCHEMBL9110426 | 0.71 | KDM4E (0.57) | KDM4EGPR3ALDH1A1HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007051119-A1 | METHODS AND COMPOSITIONS OF PARP INHIBITORS AS POTENTIATORS IN CANCER THERAPY | MGI GP, INC. (US) | 2007-05-03 | — | — | WO | claimed |
| US-9173395-B2 | Use of substituted isoquinolinones, isoquinolindiones, isoquinolintriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-03 | — | — | US | disclosed |
| US-20140302987-A1 | USE OF SUBSTITUTED ISOQUINOLINONES, ISOQUINOLINDIONES, ISOQUINOLINTRIONES AND DIHYDROISOQUINOLINONES OR IN EACH CASE SALTS THEREOF AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-09 | — | — | US | disclosed |
| WO-2007051119-A8 | METHODS AND COMPOSITIONS OF PARP INHIBITORS AS POTENTIATORS IN CANCER THERAPY | MGI GP INC (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007051119-A1 | METHODS AND COMPOSITIONS OF PARP INHIBITORS AS POTENTIATORS IN CANCER THERAPY | MGI GP, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007051119-A1 | METHODS AND COMPOSITIONS OF PARP INHIBITORS AS POTENTIATORS IN CANCER THERAPY | MGI GP, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| EP-1339402-A2 | BENZOAZEPINE AND BENZODIAZEPINE DERIVATIVES AND THEIR USE AS PARP INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002044183-A2 | BENZOAZEPINE AND BENZODIAZEPINE DERIVATIVES AND THEIR USE AS PARP INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140302987-A1 | USE OF SUBSTITUTED ISOQUINOLINONES, ISOQUINOLINDIONES, ISOQUINOLINTRIONES AND DIHYDROISOQUINOLINONES OR IN EACH CASE SALTS THEREOF AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | NQO1, NFE2, NDUFS1 | PARP1 2465/4885KDM4E 3457/4885GPR3 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.